Biotechnology

French Biotech TargEDys® Announces Positive Results of Its Clinical Trial With Its Probiotic Strain Hafnia alvei HA4597™ on the Weight Loss Thanks to Regulation of Appetite

PARIS, Feb. 6, 2020 /PRNewswire/ -- TargEDys® announces the successful completion of its 3 months, randomized, double blind, placebo-controlled, multicentric clinical study carried out on 229 subjects and evaluating the efficacy ofHafnia alvei HA4597™ in the weight loss by regulation of the appe...

2020-02-06 09:07 702

Breakthrough Study Makes Cancer Detection Possible With a Simple Blood Test; Introduces a New Systemic Hallmark of Cancer

MUMBAI, India, Feb. 6, 2020 /PRNewswire/ -- A new study  by scientists from India, USA, and UK has presented clinical evidence for an innovative test that can detect clusters of cancer cells in the blood of asymptomatic individuals as a...

2020-02-06 08:00 605

Inovio Publishes Patient Benefit Results From A Pilot Clinical Study in Recurrent Respiratory Papillomatosis (RRP), A Rare Disease Caused by HPV Infections

PLYMOUTH MEETING, Pennsylvania, Feb. 3, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced publication of data from its pilot clinical study of INO-3106, a novel DNA therapy targeting human papilloma virus type 6 (HPV 6) for the treatment of recurrent respiratory pap...

2020-02-03 21:00 417

GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma

- Belantamab mafodotin accepted for accelerated assessment by the EMA's Committee for Human Medicinal Products (CHMP) - Submission based on data from the pivotal DREAMM-2 study of immunoconjugate targeting B-cell maturation antigen (BCMA) recently published inThe Lancet Oncology LONDON, Feb. 3,...

2020-02-03 17:00 8049

Oxford Nanopore Sequencers Have Left UK for China, to Support Rapid, Near-sample Coronavirus Sequencing for Outbreak Surveillance

OXFORD, England, Feb. 3, 2020 /PRNewswire/ -- Following extensive support of, and collaboration with, public health professionals inChina, Oxford Nanopore has shipped an additional 200 MinION sequencers and related consumables toChina . These will be used to support the ongoing surveillance of the...

2020-02-03 05:20 627

Coronavirus: New Gear Offers Protection For Patients And Healthcare Workers

MIAMI, Jan. 31, 2020 /PRNewswire/ -- In the ongoing war against Coronavirus, a new technology can provide much-needed protection and benefits for patients and healthcare workers.Radiation Shield Technologies' Demron Chemical Biological Radiological and Nuclear suits have patented thermal conducti...

2020-01-31 07:02 560

Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China

Agreement will facilitate clinical trial translations in China PLYMOUTH MEETING, Pa., Jan. 30, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that it is collaborating with Beijing Advaccine Biotechnology Co. to advance the development inChina of INO-4800, Inovio'...

2020-01-30 19:00 925

Abcam Expands Cell Engineering Capabilities Through Asset Purchase of Applied StemCell's Gene Editing Platform and Oncology Product Portfolio

CAMBRIDGE, England and MILPITAS, Calif., Jan. 30, 2020 /PRNewswire/ -- Abcam plc, a global innovator in life science reagents and tools, is today pleased to announce the asset purchase of the gene editing platform and oncology product portfolio of Applied StemCell, Inc. (ASC) for life science res...

2020-01-30 15:00 462

MiRXES collaborates with NUS and DxD Hub to move Singapore to the forefront of global microRNA research and application

SINGAPORE, Jan. 29, 2020 /PRNewswire/ -- MiRXES, a leading Singaporean biotech start-up in microRNA[1] (miRNA) technology and diagnostics, collaborated with NUS and DxD Hub to mark the tenth year of miRNA research and clinical translation inSingapore. These organizations jointly led a non-coding ...

2020-01-29 10:00 543

WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus

SHANGHAI, Jan. 29, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, has stepped up its efforts in enabling the development of multipl...

2020-01-29 10:00 929

CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib

SUZHOU, China, Jan. 24, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) recently announced that it has dosed the first patient inAustralia in a clinical trial of CS1001, an investigational PD-L1 inhibitor developed by CStone, in combination with regorafenib, an...

2020-01-24 14:26 1445

CyberMDX Research Team Discovers Collection of GE Medical Device Vulnerabilities -- "MDhex"

CISA ICS has Issued an Advisory Containing 6 High-Severity CVEs for GE CARESCAPE, ApexPro, and Clinical Information Center (CIC) systems NEW YORK, Jan. 24, 2020 /PRNewswire/ -- A collection of six cybersecurity vulnerabilities has been discovered in a range of GE Healthcare devices popular ...

2020-01-24 02:48 576

Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus

PLYMOUTH MEETING, Pa., Jan. 24, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded Inovio a grant of up to$9 million to develop a vaccine against the recently emerged strain of coronavirus (2019-nCo...

2020-01-24 00:26 1167

Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody

HANGZHOU and SHAOXING, China, Jan. 23, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis, 1672.HK) announces today the approval for ASC22 to conduct clinical trials in chronic hepatitis B patients inChina from China's National Medical Products Administration. ASC22 is a first-in-class, subcuta...

2020-01-23 09:52 1385

Cognate BioServices closes Series B and completes acquisition of Cobra Biologics

MEMPHIS, Tennessee, Jan. 21, 2020 /PRNewswire/ -- Cognate BioServices, a leading contract development and manufacturing organization (CDMO) specialized in cell and cell-mediated gene therapy products today announced that it has completed the acquisition of Cobra Biologics, a leading CDMO speciali...

2020-01-22 08:04 493

China-Based Ivy Capital Invests in Betagenon's Clinical Stage AMPK Activator Program

STOCKHOLM, Jan. 20, 2020 /PRNewswire/ -- Balticgruppen Bio, the Umea based Biotech company focused on development of AMPK activator compounds, operating under the trademark Betagenon, has closed a funding round withChina based asset management firm Ivy Capital granting the company 3 MUSD of fundi...

2020-01-20 11:14 375

QBiotics receives first registration for tigilanol tiglate with European Medicines Agency approval of Stelfonta(R)

* STELFONTA® (tigilanol tiglate) approved by the European Medicines Agency (EMA), making it the first pharmaceutical treatment available for all grades of canine non-metastatic mast cell tumours (MCT)[1] * The approval marks the first registration of QBiotic's, lead compound tigilanol tiglate...

2020-01-20 07:00 705

Innovent Out-Licenses Commercial Rights for Avastin® Biosimilar to Coherus BioSciences in the United States and Canada

SUZHOU, China, Jan. 14, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or the "Company") (HKEX: 01801), a biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today announced tha...

2020-01-14 08:00 12157

Evolution 2.0 Prize: Unprecedented $10 Million Offered To Replicate Cellular Evolution

CHICAGO, Jan. 14, 2020 /PRNewswire/ --  An incentive prize ten times the size of the Nobel – believed to be the largest single award ever in basic science – is being offered to the person or team solving the largest mystery in history: how genetic code inside cells got there, and how cells intent...

2020-01-14 03:23 559

Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular degeneration (AMD) and Diabetic Macular Oedema (DMO)

The program, facilitated by Johnson & Johnson Innovation, has the potential to improve the treatment of patients with retinal vascular diseases and transform the lives of those suffering from vision loss. CAMBRIDGE, England, Jan. 13, 2020 /PRNewswire/ -- Exonate, an early stage biotechnology com...

2020-01-13 16:00 448
12345 ... 57